BioNTech (NASDAQ:BNTX) CEO Sells $4,077,450.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 41,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00. Following the completion of the transaction, the chief executive officer owned 602,209 shares of the company’s stock, valued at approximately $59,889,685.05. The trade was a 6.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Down 0.9%

Shares of NASDAQ BNTX opened at $95.83 on Thursday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The firm has a market capitalization of $24.23 billion, a PE ratio of -12.24 and a beta of 1.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $97.17 and a two-hundred day moving average price of $95.00.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue was down 59.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.60) EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC raised its holdings in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the second quarter worth $39,000. Caitong International Asset Management Co. Ltd boosted its holdings in BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after purchasing an additional 506 shares in the last quarter. Vestcor Inc acquired a new position in BioNTech during the fourth quarter worth $153,000. Finally, Rockefeller Capital Management L.P. increased its position in BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BNTX has been the topic of several research reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Canaccord Genuity Group decreased their target price on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Morgan Stanley dropped their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.